English
Polski
Español
українська
2015 ACR-EULAR guidelines on management of polymyalgia rheumatica
In 2015, the ACR and the EULAR published new guidelines on the management of PMR. What do they change in clinical practice?
2016-06-18
In 2015, the ACR and the EULAR published new guidelines on the management of PMR. What do they change in clinical practice?
What are the emerging treatment modalities for osteoporosis?
In 2012, the ACR and the EULAR have defined new classification criteria for PMR. Are these criteria effective in clinical practice? What have been the major changes introduced in the last update?
Bearing in mind the availability of more personalized treatments nowadays, are there some subgroups of patients with osteoporosis that would specifically benefit from certain drugs?
Could you comment on the new drugs used in spondyloarthritis?
Are steroids still the mainstay treatment for giant cell arteritis? Are there perspectives for new therapies with fewer adverse effects?
Which study is superior in the diagnostics of patients with giant cell arteritis: ultrasound or temporal artery biopsy?
How should we assess response to treatment in patients with ANCA-associated vasculitis?
Can clinicians use the Chapel Hill Consensus Conference definitions, European Medicines Agency (EMA) algorithm, or American College of Rheumatology (ACR) classification criteria in the diagnostic workup of patients with vasculitis?
Diagnosis of ANCA-associated vasculitis seems to be much easier with ANCA testing being widely available. Can we confirm or exclude ANCA-associated vasculitis based on the ANCA test result?
